Evidence map›Paper›PMID 33748935›Full record

ArticleJournal of computer-aided molecular design2021

In silico modeling of PAX8-PPARγ fusion protein in thyroid carcinoma: influence of structural perturbation by fusion on ligand-binding affinity.

Kaori Sakaguchi, Yoshio Okiyama, Shigenori Tanaka

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kaori SakaguchiGraduate School of System Informatics, Kobe University, 1-1 Rokkodai, Nada-ku, Kobe, 657-8501, Japan. sakaguchi@eniac.scitec.kobe-u.ac.jp.ORCID 0000-0003-1950-8851
Yoshio OkiyamaDivision of Medicinal Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, 210-9501, Japan. okiyama@nihs.go.jp.ORCID 0000-0002-6775-8604
Shigenori TanakaGraduate School of System Informatics, Kobe University, 1-1 Rokkodai, Nada-ku, Kobe, 657-8501, Japan. tanaka2@kobe-u.ac.jp.ORCID 0000-0002-6659-2788

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paired box 8 (PAX8)-peroxisome proliferator-activated receptor γ (PPARγ) rearrangement is believed to play an important role in tumorigenesis of PAX8-PPARγ fusion protein (PPFP) thyroid carcinomas, while without establishing any standard treatment, including drugs. Although PPFP is a potential promising target for therapeutic agents, the three-dimensional (3D) structure and functions have not yet been experimentally elucidated. In this study, we aimed to construct the 3D structure of PPFP and to aid in the development of therapies that can target PPFP for thyroid carcinomas. The 3D structure of PPFP was constructed by homology modeling based on crystallographic structure data. To validate the modeled structure, we analyzed the thermal fluctuations by molecular dynamics simulations and predicted the physical properties using bioinformatic analyses. We found that the modeled structure was stable under hydrated conditions and had features indicating the actual existence of the structure. Furthermore, the binding free energies of the ligand rosiglitazone with PPARγ and PPFP were evaluated by the molecular mechanics-Poisson-Boltzmann surface area method. We found that rosiglitazone has different binding affinities for the same binding pockets of PPARγ and PPFP, and the optimal compound for PPFP can differ from that of PPARγ. This suggests the need for the development of drugs targeting PPFP that allow for the fusion, rather than focusing on the PPARγ side of PPFP and searching for the best compounds for that pocket. Our findings are expected to lead to the development of new therapies for thyroid tumors.

Indexed as

Drug DiscoveryAntineoplastic AgentsBinding SitesHumansHypoglycemic AgentsLigandsModels, MolecularOncogene Proteins, FusionProtein ConformationRosiglitazoneThermodynamicsThyroid NeoplasmsAntineoplastic AgentsHypoglycemic AgentsLigandsOncogene Proteins, FusionPAX8-PPARgamma fusion protein, humanRosiglitazoneFollicular thyroid neoplasiaMM-PBSAMolecular dynamics simulationMolecular modelingPAX8–PPARγ fusion proteinProtein–ligand binding

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.